BioCentury | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

...Stockholm, Sweden) named Thomas Knittel CMO. He was EVP of medical and scientific development at Prima BioMed Ltd....
BioCentury | Aug 11, 2017
Strategy

The flip-side of immunotherapy

...ligand Bispecific mAb targeting BLyS (BAFF) and ICOSLG Phase I GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) / Prima BioMed Ltd....
...licensed the anti- LAG3 mAb IMP731 from cancer play Immutep S.A. Immutep was acquired by Prima Biomed Ltd....
...IFM Therapeutics Inc., Boston, Mass. ImCheck Therapeutics S.A.S., Marseille, France Innate Pharma S.A.(Euronext:IPH), Marseille, France Prima BioMed Ltd....
BioCentury | Jun 9, 2017
Clinical News

Prima reports response data from Phase IIb of IMP321 in breast cancer

...Ig and a dimeric protein with 4 extracellular domains of lymphocyte-activation gene 3 (LAG3; CD223). Prima BioMed Ltd....
BioCentury | Apr 27, 2017
Clinical News

IMP321: Ph I TACTI-mel ongoing

...of 1, 6 and 30 mg IMP321 and plans to enroll up to 18 patients. Prima BioMed Ltd....
BioCentury | Jan 13, 2017
Clinical News

IMP321: Interim Ph IIb AIPAC data

...tolerated and increased levels of blood monocytes, dendritic cells and CD8 T cells. This month, Prima BioMed...
...double-blind portion of the trial evaluating 30 mg IMP321 plus paclitaxel vs. placebo plus paclitaxel. Prima BioMed Ltd....
BioCentury | Jan 3, 2017
Clinical News

IMP321: Ph I TACTI-mel ongoing

...evaluating 1, 6 and 30 mg IMP321 and plans to enroll up to 24 patients. Prima BioMed Ltd....
BioCentury | Apr 18, 2016
Clinical News

IMP321: Phase I/IIa data

...Keytruda pembrolizumab is in the Phase I TACTI-mel trial to treat unresectable or metastatic melanoma. Prima BioMed Ltd....
BioCentury | Mar 7, 2016
Clinical News

IMP321: Phase IIb started

...this is the first time a patient in the EU has received a Chinese-manufactured biologic. Prima BioMed Ltd....
BioCentury | Mar 3, 2016
Clinical News

First EU trial begins of Chinese-made biologic

...Shanghai that is due to be operational in 2017 (see BioCentury Extra, Jan. 8) . Prima BioMed...
BioCentury | Feb 1, 2016
Clinical News

IMP321: Phase I started

...TACTI-mel trial to evaluate IMP321 in combination with Keytruda pembrolizumab in up to 24 patients. Prima BioMed Ltd....
Items per page:
1 - 10 of 73
BioCentury | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

...Stockholm, Sweden) named Thomas Knittel CMO. He was EVP of medical and scientific development at Prima BioMed Ltd....
BioCentury | Aug 11, 2017
Strategy

The flip-side of immunotherapy

...ligand Bispecific mAb targeting BLyS (BAFF) and ICOSLG Phase I GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) / Prima BioMed Ltd....
...licensed the anti- LAG3 mAb IMP731 from cancer play Immutep S.A. Immutep was acquired by Prima Biomed Ltd....
...IFM Therapeutics Inc., Boston, Mass. ImCheck Therapeutics S.A.S., Marseille, France Innate Pharma S.A.(Euronext:IPH), Marseille, France Prima BioMed Ltd....
BioCentury | Jun 9, 2017
Clinical News

Prima reports response data from Phase IIb of IMP321 in breast cancer

...Ig and a dimeric protein with 4 extracellular domains of lymphocyte-activation gene 3 (LAG3; CD223). Prima BioMed Ltd....
BioCentury | Apr 27, 2017
Clinical News

IMP321: Ph I TACTI-mel ongoing

...of 1, 6 and 30 mg IMP321 and plans to enroll up to 18 patients. Prima BioMed Ltd....
BioCentury | Jan 13, 2017
Clinical News

IMP321: Interim Ph IIb AIPAC data

...tolerated and increased levels of blood monocytes, dendritic cells and CD8 T cells. This month, Prima BioMed...
...double-blind portion of the trial evaluating 30 mg IMP321 plus paclitaxel vs. placebo plus paclitaxel. Prima BioMed Ltd....
BioCentury | Jan 3, 2017
Clinical News

IMP321: Ph I TACTI-mel ongoing

...evaluating 1, 6 and 30 mg IMP321 and plans to enroll up to 24 patients. Prima BioMed Ltd....
BioCentury | Apr 18, 2016
Clinical News

IMP321: Phase I/IIa data

...Keytruda pembrolizumab is in the Phase I TACTI-mel trial to treat unresectable or metastatic melanoma. Prima BioMed Ltd....
BioCentury | Mar 7, 2016
Clinical News

IMP321: Phase IIb started

...this is the first time a patient in the EU has received a Chinese-manufactured biologic. Prima BioMed Ltd....
BioCentury | Mar 3, 2016
Clinical News

First EU trial begins of Chinese-made biologic

...Shanghai that is due to be operational in 2017 (see BioCentury Extra, Jan. 8) . Prima BioMed...
BioCentury | Feb 1, 2016
Clinical News

IMP321: Phase I started

...TACTI-mel trial to evaluate IMP321 in combination with Keytruda pembrolizumab in up to 24 patients. Prima BioMed Ltd....
Items per page:
1 - 10 of 73